Spaces:
Sleeping
Sleeping
Salma Hassan
commited on
Commit
·
3e83720
1
Parent(s):
bb560ec
Enhance app.py by adding a scrollable container for content, improving layout and user experience. Adjust CSS styles to ensure proper overflow handling and maintain visual consistency in the Clinical Trial Matching Chatbot.
Browse files
app.py
CHANGED
|
@@ -426,7 +426,13 @@ if __name__ == "__main__":
|
|
| 426 |
.gr-markdown table td:nth-child(6) {
|
| 427 |
max-width: 70px !important;
|
| 428 |
}
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 429 |
</style>
|
|
|
|
| 430 |
""")
|
| 431 |
|
| 432 |
gr.Markdown("# 🏥 Clinical Trial Matching Chatbot")
|
|
@@ -507,5 +513,6 @@ if __name__ == "__main__":
|
|
| 507 |
["A 67-year-old male with relapsed/refractory multiple myeloma presents for enrollment into a post-trial access study. He previously participated in a Pfizer-sponsored parent study evaluating elranatamab, during which he achieved a partial response and remained clinically stable. At the time the parent trial ended, he was continuing on elranatamab with no evidence of disease progression or significant toxicity. He reports no history of psychiatric illness or lab abnormalities, and he wishes to continue treatment through this access program."]
|
| 508 |
]
|
| 509 |
)
|
| 510 |
-
|
|
|
|
| 511 |
demo.launch(share=True)
|
|
|
|
| 426 |
.gr-markdown table td:nth-child(6) {
|
| 427 |
max-width: 70px !important;
|
| 428 |
}
|
| 429 |
+
|
| 430 |
+
.scroll-container {
|
| 431 |
+
max-height: 90vh;
|
| 432 |
+
overflow-y: auto;
|
| 433 |
+
padding-right: 10px;}
|
| 434 |
</style>
|
| 435 |
+
<div class="scroll-container">
|
| 436 |
""")
|
| 437 |
|
| 438 |
gr.Markdown("# 🏥 Clinical Trial Matching Chatbot")
|
|
|
|
| 513 |
["A 67-year-old male with relapsed/refractory multiple myeloma presents for enrollment into a post-trial access study. He previously participated in a Pfizer-sponsored parent study evaluating elranatamab, during which he achieved a partial response and remained clinically stable. At the time the parent trial ended, he was continuing on elranatamab with no evidence of disease progression or significant toxicity. He reports no history of psychiatric illness or lab abnormalities, and he wishes to continue treatment through this access program."]
|
| 514 |
]
|
| 515 |
)
|
| 516 |
+
gr.HTML("</div>")
|
| 517 |
+
|
| 518 |
demo.launch(share=True)
|